The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19

Chia Siang Kow, Syed Shahzad Hasan

Research output: Contribution to journalLetterpeer-review

Abstract

Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.
Original languageEnglish
Pages (from-to)2035
Number of pages1
JournalObesity
Volume28
Issue number11
Early online date21 Jul 2020
DOIs
Publication statusPublished - 1 Nov 2020

Fingerprint Dive into the research topics of 'The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19'. Together they form a unique fingerprint.

Cite this